Related Experiment Video
Updated: Jan 18, 2026
MRI-guided Focused Ultrasound Thalamotomy for Patients with Medically-refractory Essential Tremor
Published on: December 13, 2017
Current and Emerging Therapeutic Targets for Essential Tremor: A Critical Appraisal of Recent Preclinical and
Adreesh Mukherjee1, Sanjay Pandey2
1Department of Neurology, North Bengal Medical College, Darjeeling, India.
Background:
Essential tremor (ET) is a common hyperkinetic movement disorder and causes significant disability. However, the response to the commonly used medications is often unsatisfactory. Hence, there is a requirement for improved treatment modalities involving novel therapeutic targets.
Objective:
To review the literature on the recent clinical and preclinical studies regarding the treatment of ET, to identify and discuss the emerging therapeutic targets.
Methods:
The authors conducted a literature search on PubMed and Scopus on March 25, 2025 using different search terms and included the relevant articles in the review. Ongoing clinical trials in ET were noted by searching https://clinicaltrials.gov/.
Results:
Evidence collected from preclinical studies has led to clinical trials on several pharmacological agents such as T-type calcium channel antagonists, GABAA receptor modulators, SK channel modulators, and agents targeting glutamatergic neurotransmission. However, some promising clinical trials had negative results, and the outcomes of the other phase 2 and 3 studies are still pending. Preclinical studies have identified other pharmacological targets that have yet to be replicated in clinical studies. Regarding deep brain stimulation and magnetic resonance-guided focused ultrasound surgery, in addition to the thalamic ventralis intermedius nucleus, the posterior subthalamic area has also shown efficacy, possibly due to its proximity to the dentato-rubro-thalamic tract. Non-invasive brain, spinal cord, and peripheral stimulation techniques are the other potential treatment modalities investigated in ET.
Conclusions:
New therapeutic targets including pharmacological, surgical, and non-invasive stimulation techniques have shown promise in ET. Translating preclinical research into useful treatment strategies requires further clinical trials.
More Related Videos
Related Concept Videos
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
01:24Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
01:31Skeletal Muscle Relaxants: Therapeutic Uses
01:26Cholinergic Antagonists: Therapeutic Uses
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...
01:26Targets for Drug Action: Overview
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
01:24Centrally Acting Muscle Relaxants: Therapeutic Uses
Centrally acting drugs are classified into spasmolytic and antispasmodic drugs. Spasmolytic drugs such as baclofen, diazepam, and tizanidine inhibit spinal motor neurons and decrease muscle tone. Spasmolytic drugs are administered for severe and chronic spasms due to multiple sclerosis, cerebral palsy, stroke, and spinal cord and muscle injuries. However,...